Febuxostat (Uloric)|5mg|K1381-上海高创化学科技有限公司

SKU:K1381		M. Wt:316.37
Formula:C16H16N2O3S		Solubility:No
Purity:>99%		Storage:2 years at -20 degrees centigrade
CAS No.:144060-53-7		Synonyms:Adenuric
Chemical NameN/A

Description	Febuxostat (Uloric)
Targets	XO
IC50	0.6 nM
In vitro	Febuxostat displays potent mixed-type inhibition of the activity of purified bovine milk XO, with Ki and Ki' values of 0.6 and 3.1 nM respectively. Febuxostat(TMX-67), a newly synthesized xanthine oxidase/xanthine dehydrogenase (XOD/XDH) inhibitor, has almost no effect on DNFB-sensitized mice.[1] At concentrations up to 100 muM, febuxostat has no significant effects on the activities of the following enzymes of purine and pyrimidine metabolism: guanine deaminase, hypoxanthine-guanine phosphoribosyltransferase, purine nucleoside phosphorylase, orotate phosphoribosyltransferase and orotidine-5'-monophosphate decarboxylase.[2]
In vivo	Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.[3] Daily febuxostat doses in the range 10 mg to 120 mg resulted in proportional mean serum urate reductions ranging from 25% to 70% and in proportional increases in maximum febuxostat plasma concentrations and area under plasma concentration versus time curves.[4]
Clinical Trials	N/A
Features	N/A

Description

Febuxostat (Uloric)

Targets

IC50

0.6 nM

In vitro

Febuxostat displays potent mixed-type inhibition of the activity of purified bovine milk XO, with Ki and Ki' values of 0.6 and 3.1 nM respectively. Febuxostat(TMX-67), a newly synthesized xanthine oxidase/xanthine dehydrogenase (XOD/XDH) inhibitor, has almost no effect on DNFB-sensitized mice.[1] At concentrations up to 100 muM, febuxostat has no significant effects on the activities of the following enzymes of purine and pyrimidine metabolism: guanine deaminase, hypoxanthine-guanine phosphoribosyltransferase, purine nucleoside phosphorylase, orotate phosphoribosyltransferase and orotidine-5'-monophosphate decarboxylase.[2]

In vivo

Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.[3] Daily febuxostat doses in the range 10 mg to 120 mg resulted in proportional mean serum urate reductions ranging from 25% to 70% and in proportional increases in maximum febuxostat plasma concentrations and area under plasma concentration versus time curves.[4]

Clinical Trials

N/A

Features

N/A

工商信息

企业名称

上海高创化学科技有限公司

企业信息已认证

企业类型

信用代码

310228001353263

成立日期

2010-06-05

注册资本

经营范围

从事化学科技、计算机领域内技术开发、技术咨询、技术服务,从事生物科技领域内技术开发、技术咨询,化学试剂、化工原料及产品(除危险化学品、监控化学品、烟花爆竹、民用爆炸物品、易制毒化学品),实验室设备(除医疗器械),仪器仪表,Ⅰ类医疗器械,金属制品,电子产品,机电产品销售。【依法须经批准的项目,经相关部门批准后方可开展经营活动】

Febuxostat (Uloric)由上海高创化学科技有限公司为您提供，货号K1381，规格：5mg，CAS号：144060-53-7，如您想了解更多关于Febuxostat (Uloric)价格、Febuxostat (Uloric)结构式、批发、用途等信息，欢迎咨询。除供应Febuxostat (Uloric)外，还可为您提供Gibco马血清（新西兰）、重组人半乳糖凝集素3/Human LGALS3 His、特级新生牛血清（无支原体）等试剂，公司有专业的客户服务团队，是您值得信赖的合作伙伴，上海高创客户服务电话，售前、售后均可联系。